Targeting survivin using a combination of miR-494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growth

Castration-resistant prostate cancer (CRPC) remains an obstacle in the current treatment provided for prostate cancer (PCa). Survivin, an apoptosis inhibitor, has been found to be involved in the progression of PCa, and is a promising candidate target for CRPC therapy. Micro (mi) RNAs are involved i...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, JIN, SUN, CHENWEN, WANG, LIPING, XU, MING, ZANG, YACHEN, ZHOU, YIBIN, LIU, XIAOLONG, TAO, WEI, XUE, BOXIN, SHAN, YUXI, YANG, DONGRONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732832/
https://www.ncbi.nlm.nih.gov/pubmed/26718651
http://dx.doi.org/10.3892/mmr.2015.4739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732832/
https://www.ncbi.nlm.nih.gov/pubmed/26718651
http://dx.doi.org/10.3892/mmr.2015.4739

Ejemplares similares